AKT1 and cancer: Therapeutic inhibition of the PI3K/AKT1 pathway has been proposed as a strategy to disrupt HR and sensitize cancer cells to PARP inhibition (56), and a nonrandomized trial of the pan-AKT inhibitor capivasertib suggested that AKT1E17K is a therapeutic target in metastatic solid tumors (57).